ID

43559

Description

Hepsera Versus Hepsera Plus Lamivudine for Treatment of Chronic Hepatitis B in Patients With Normal ALT; ODM derived from: https://clinicaltrials.gov/show/NCT00230477

Lien

https://clinicaltrials.gov/show/NCT00230477

Mots-clés

Versions (2)
  1. 17/09/2016 17/09/2016 -
  2. 20/09/2021 20/09/2021 -
Téléchargé le

20 septembre 2021

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Hepatitis B NCT00230477

Anglais

Eligibility Hepatitis B NCT00230477

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
older than 18 years
Description

Age

Type de données

boolean

Alias
UMLS CUI [1]
C0001779
hbsag+ at screening and for at least 6 months prior to study entry
Description

Hepatitis B surface antigen positive

Type de données

boolean

Alias
UMLS CUI [1]
C0149709
hbeag+
Description

Hepatitis B e antigen positive

Type de données

boolean

Alias
UMLS CUI [1]
C0392390
hbv dna greater than 6 log10 copies/ml
Description

Hepatitis B DNA Measurement

Type de données

boolean

Alias
UMLS CUI [1]
C3641250
platelet count greater than 50,000 platelets/mm3
Description

Platelet Count measurement

Type de données

boolean

Alias
UMLS CUI [1]
C0032181
hemoglobin greater than 7.5 g/dl
Description

Hemoglobin

Type de données

boolean

Alias
UMLS CUI [1]
C0019046
alt less than uln
Description

Alanine aminotransferase measurement

Type de données

boolean

Alias
UMLS CUI [1]
C0201836
estimated creatine clearance>50 ml/min as estimated by the crockcroft-gault equation ((140-age) x (kg)/(serum creatine x 72) (for women x 0.85))
Description

Estimation of creatinine clearance by Cockcroft-Gault formula

Type de données

boolean

Alias
UMLS CUI [1]
C2711451
female and male participants must be practicing an effective form of contraception (male or female condom with spermicide, diaphragm or cervical cap with spermicide, intrauterine device, hormonal contraception)
Description

Gender Contraceptive methods | Condoms, Male | Female Condoms | Spermicide | Vaginal contraceptive diaphragm | CERVICAL CAP FOR CONTRACEPTIVE USE | Intrauterine Devices | Hormonal contraception

Type de données

boolean

Alias
UMLS CUI [1,1]
C0079399
UMLS CUI [1,2]
C0700589
UMLS CUI [2]
C0009653
UMLS CUI [3]
C0221829
UMLS CUI [4]
C1144908
UMLS CUI [5]
C0042241
UMLS CUI [6]
C0493327
UMLS CUI [7]
C0021900
UMLS CUI [8]
C2985296
serum alpha-fetoprotein less than 50 ng/ml within 30 days of study entry
Description

serum alpha-fetoprotein (AFP) measurement

Type de données

boolean

Alias
UMLS CUI [1]
C0546833
childs-pugh score less than 7 and no ascites, variceal bleeding, or hepatic encephalopathy
Description

Child-Pugh Classification | Ascites | Bleeding varices | Hepatic Encephalopathy

Type de données

boolean

Alias
UMLS CUI [1]
C4050412
UMLS CUI [2]
C0003962
UMLS CUI [3]
C0333106
UMLS CUI [4]
C0019151
able to give written informed consent and to comply with the study protocol
Description

Informed Consent | Protocol Compliance

Type de données

boolean

Alias
UMLS CUI [1]
C0021430
UMLS CUI [2]
C0525058
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
history or evidence of hiv, hepatitis c or hepatitis d
Description

HIV Evidence of | Hepatitis C Evidence of | Hepatitis D Infection Evidence of

Type de données

boolean

Alias
UMLS CUI [1,1]
C0019682
UMLS CUI [1,2]
C0332120
UMLS CUI [2,1]
C0019196
UMLS CUI [2,2]
C0332120
UMLS CUI [3,1]
C0011226
UMLS CUI [3,2]
C0332120
known or suspected hypersensitivity to adefovir or other nucleoside/nucleotide analogs.
Description

Hypersensitivity adefovir | Hypersensitivity Nucleoside Analogs | Hypersensitivity nucleotide analog

Type de données

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0050175
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C1579410
UMLS CUI [3,1]
C0020517
UMLS CUI [3,2]
C0597107
history of clinically significant renal dysfunction
Description

Renal dysfunction Clinical Significance

Type de données

boolean

Alias
UMLS CUI [1,1]
C3279454
UMLS CUI [1,2]
C2826293
any active medical or psychiatric illness that, in the opinion of the investigator, would interfere with subject treatment, assessment, or compliance with the protocol
Description

Illness Interferes with Therapeutic procedure | Mental disorder Interferes with Therapeutic procedure | Illness Interferes with Protocol Compliance | Mental disorder Interferes with Protocol Compliance

Type de données

boolean

Alias
UMLS CUI [1,1]
C0221423
UMLS CUI [1,2]
C0521102
UMLS CUI [1,3]
C0087111
UMLS CUI [2,1]
C0004936
UMLS CUI [2,2]
C0521102
UMLS CUI [2,3]
C0087111
UMLS CUI [3,1]
C0221423
UMLS CUI [3,2]
C0521102
UMLS CUI [3,3]
C0525058
UMLS CUI [4,1]
C0004936
UMLS CUI [4,2]
C0521102
UMLS CUI [4,3]
C0525058
pregnancy or breastfeeding
Description

Pregnancy | Breast Feeding

Type de données

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
receipt of systemic corticosteroids within 90 days of study entry
Description

systemic steroids

Type de données

boolean

Alias
UMLS CUI [1]
C2825233
receipt of nephrotoxic drugs within 8 weeks prior to study screening or expected use of these agents during the course of the study
Description

Pharmaceutical Preparations Nephrotoxic

Type de données

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C1514118
Retour au début de la page

Similar models

Eligibility Hepatitis B NCT00230477

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
older than 18 years
boolean
C0001779 (UMLS CUI [1])
Hepatitis B surface antigen positive
Item
hbsag+ at screening and for at least 6 months prior to study entry
boolean
C0149709 (UMLS CUI [1])
Hepatitis B e antigen positive
Item
hbeag+
boolean
C0392390 (UMLS CUI [1])
Hepatitis B DNA Measurement
Item
hbv dna greater than 6 log10 copies/ml
boolean
C3641250 (UMLS CUI [1])
Platelet Count measurement
Item
platelet count greater than 50,000 platelets/mm3
boolean
C0032181 (UMLS CUI [1])
Hemoglobin
Item
hemoglobin greater than 7.5 g/dl
boolean
C0019046 (UMLS CUI [1])
Alanine aminotransferase measurement
Item
alt less than uln
boolean
C0201836 (UMLS CUI [1])
Estimation of creatinine clearance by Cockcroft-Gault formula
Item
estimated creatine clearance>50 ml/min as estimated by the crockcroft-gault equation ((140-age) x (kg)/(serum creatine x 72) (for women x 0.85))
boolean
C2711451 (UMLS CUI [1])
Gender Contraceptive methods | Condoms, Male | Female Condoms | Spermicide | Vaginal contraceptive diaphragm | CERVICAL CAP FOR CONTRACEPTIVE USE | Intrauterine Devices | Hormonal contraception
Item
female and male participants must be practicing an effective form of contraception (male or female condom with spermicide, diaphragm or cervical cap with spermicide, intrauterine device, hormonal contraception)
boolean
C0079399 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
C0009653 (UMLS CUI [2])
C0221829 (UMLS CUI [3])
C1144908 (UMLS CUI [4])
C0042241 (UMLS CUI [5])
C0493327 (UMLS CUI [6])
C0021900 (UMLS CUI [7])
C2985296 (UMLS CUI [8])
serum alpha-fetoprotein (AFP) measurement
Item
serum alpha-fetoprotein less than 50 ng/ml within 30 days of study entry
boolean
C0546833 (UMLS CUI [1])
Child-Pugh Classification | Ascites | Bleeding varices | Hepatic Encephalopathy
Item
childs-pugh score less than 7 and no ascites, variceal bleeding, or hepatic encephalopathy
boolean
C4050412 (UMLS CUI [1])
C0003962 (UMLS CUI [2])
C0333106 (UMLS CUI [3])
C0019151 (UMLS CUI [4])
Informed Consent | Protocol Compliance
Item
able to give written informed consent and to comply with the study protocol
boolean
C0021430 (UMLS CUI [1])
C0525058 (UMLS CUI [2])
Item Group
C0680251 (UMLS CUI)
HIV Evidence of | Hepatitis C Evidence of | Hepatitis D Infection Evidence of
Item
history or evidence of hiv, hepatitis c or hepatitis d
boolean
C0019682 (UMLS CUI [1,1])
C0332120 (UMLS CUI [1,2])
C0019196 (UMLS CUI [2,1])
C0332120 (UMLS CUI [2,2])
C0011226 (UMLS CUI [3,1])
C0332120 (UMLS CUI [3,2])
Hypersensitivity adefovir | Hypersensitivity Nucleoside Analogs | Hypersensitivity nucleotide analog
Item
known or suspected hypersensitivity to adefovir or other nucleoside/nucleotide analogs.
boolean
C0020517 (UMLS CUI [1,1])
C0050175 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C1579410 (UMLS CUI [2,2])
C0020517 (UMLS CUI [3,1])
C0597107 (UMLS CUI [3,2])
Renal dysfunction Clinical Significance
Item
history of clinically significant renal dysfunction
boolean
C3279454 (UMLS CUI [1,1])
C2826293 (UMLS CUI [1,2])
Illness Interferes with Therapeutic procedure | Mental disorder Interferes with Therapeutic procedure | Illness Interferes with Protocol Compliance | Mental disorder Interferes with Protocol Compliance
Item
any active medical or psychiatric illness that, in the opinion of the investigator, would interfere with subject treatment, assessment, or compliance with the protocol
boolean
C0221423 (UMLS CUI [1,1])
C0521102 (UMLS CUI [1,2])
C0087111 (UMLS CUI [1,3])
C0004936 (UMLS CUI [2,1])
C0521102 (UMLS CUI [2,2])
C0087111 (UMLS CUI [2,3])
C0221423 (UMLS CUI [3,1])
C0521102 (UMLS CUI [3,2])
C0525058 (UMLS CUI [3,3])
C0004936 (UMLS CUI [4,1])
C0521102 (UMLS CUI [4,2])
C0525058 (UMLS CUI [4,3])
Pregnancy | Breast Feeding
Item
pregnancy or breastfeeding
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
systemic steroids
Item
receipt of systemic corticosteroids within 90 days of study entry
boolean
C2825233 (UMLS CUI [1])
Pharmaceutical Preparations Nephrotoxic
Item
receipt of nephrotoxic drugs within 8 weeks prior to study screening or expected use of these agents during the course of the study
boolean
C0013227 (UMLS CUI [1,1])
C1514118 (UMLS CUI [1,2])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial